Evidence map›Paper›PMID 32098267›Full record

ArticleDiagnostics (Basel, Switzerland)2020

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.

Yoshimasa Kosaka, Yutaka Yamamoto, Hirokazu Tanino, Hiroshi Nishimiya, Mutsuko Yamamoto-Ibusuki, Yuko Hirota, Hirotaka Iwase, Seigo Nakamura, Sadako Akashi-Tanaka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoshimasa KosakaDepartment of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan.ORCID 0000-0001-7896-7439
Yutaka YamamotoDepartment of Breast and Endocrine Surgery, Graduate School of Medical Sciences Kumamoto University, Kumamoto 860-8556, Japan.ORCID 0000-0001-6147-6828
Hirokazu TaninoDivision of Breast Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Hiroshi NishimiyaDepartment of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan.
Mutsuko Yamamoto-IbusukiDepartment of Molecular-Targeting Therapy for Breast Cancer, Kumamoto University Hospital, Kumamoto 860-8556, Japan.ORCID 0000-0002-3529-9706
Yuko HirotaDepartment of Diagnostic Pathology, Showa University Koutou Toyosu Hospital, Koutou 135-8577, Japan.
Hirotaka IwaseDepartment of Breast and Endocrine Surgery, Graduate School of Medical Sciences Kumamoto University, Kumamoto 860-8556, Japan.
Seigo NakamuraDepartment of Breast Surgical Oncology, Showa University School of Medicine, Shinagawa 142-8666, Japan.
Sadako Akashi-TanakaDepartment of Breast Surgical Oncology, Showa University School of Medicine, Shinagawa 142-8666, Japan.ORCID 0000-0002-2065-7742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) has several subtypes. The identification of markers associated with recurrence and poor prognosis in patients with TNBC is urgently needed. BRCAness is a set of traits in which

Indexed as

BRCAnessbreast cancerneoadjuvant chemotherapyprognosistriple-negative breast cancer

Identifiers

PMID32098267
PMCPMC7168149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.